Cargando…
Noninferiority trials
Noninferiority trials are intended to show that the effect of a new treatment is not worse than that of an active control by more than a specified margin. These trials have a number of inherent weaknesses that superiority trials do not: no internal demonstration of assay sensitivity, no single conse...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59590/ https://www.ncbi.nlm.nih.gov/pubmed/11714400 http://dx.doi.org/10.1186/cvm-1-1-019 |
_version_ | 1782120079861743616 |
---|---|
author | Snapinn, Steven M |
author_facet | Snapinn, Steven M |
author_sort | Snapinn, Steven M |
collection | PubMed |
description | Noninferiority trials are intended to show that the effect of a new treatment is not worse than that of an active control by more than a specified margin. These trials have a number of inherent weaknesses that superiority trials do not: no internal demonstration of assay sensitivity, no single conservative analysis approach, lack of protection from bias by blinding, and difficulty in specifying the noninferiority margin. Noninferiority trials may sometimes be necessary when a placebo group can not be ethically included, but it should be recognized that the results of such trials are not as credible as those from a superiority trial. |
format | Text |
id | pubmed-59590 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-595902001-11-06 Noninferiority trials Snapinn, Steven M Curr Control Trials Cardiovasc Med Commentary Noninferiority trials are intended to show that the effect of a new treatment is not worse than that of an active control by more than a specified margin. These trials have a number of inherent weaknesses that superiority trials do not: no internal demonstration of assay sensitivity, no single conservative analysis approach, lack of protection from bias by blinding, and difficulty in specifying the noninferiority margin. Noninferiority trials may sometimes be necessary when a placebo group can not be ethically included, but it should be recognized that the results of such trials are not as credible as those from a superiority trial. BioMed Central 2000 2000-07-31 /pmc/articles/PMC59590/ /pubmed/11714400 http://dx.doi.org/10.1186/cvm-1-1-019 Text en Copyright © 2000 Current Controlled Trials Ltd |
spellingShingle | Commentary Snapinn, Steven M Noninferiority trials |
title | Noninferiority trials |
title_full | Noninferiority trials |
title_fullStr | Noninferiority trials |
title_full_unstemmed | Noninferiority trials |
title_short | Noninferiority trials |
title_sort | noninferiority trials |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59590/ https://www.ncbi.nlm.nih.gov/pubmed/11714400 http://dx.doi.org/10.1186/cvm-1-1-019 |
work_keys_str_mv | AT snapinnstevenm noninferioritytrials |